Skip to Content

'
Francisco Vega-Vazquez, MD PhD

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Hematopathology, Division of Pathology/Lab Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

1997 University of Navarra, Pamplona, Spain, PHD, Cell Biology
1992 College of Medicine, University Complutense of Madrid, Madrid, Spain, MD, Medicine

Postgraduate Training

7/2005-6/2006 Clinical Fellowship, Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX
3/2003-3/2005 Clinical Residency, Anatomic Pathology, Baylor College of Medicine, Houston, TX
9/2002-3/2003 Research Fellowship, Pathology, Baylor College of Medicine, Houston, TX
12/1999-8/2002 Research Fellowship, Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX
1/1994-12/1997 Clinical Residency, Anatomic Pathology, University of Navarra, Pamplona, Spain

Experience/Service

Administrative Appointments/Responsibilities

Lymphoma Section Head, Department of Hematopathology, Division of Pathology/Lab Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 1/2011-present

Honors and Awards

2006 The Janice Davis Singletary Award for Clinical Fellowship in Lymphoma, UT MD Anderson Cancer Center
1999-2001 Postgraduate Grant from the Fundacion Pedro Barrie de la Maza La Coruna, Spain, Fundacion Pedro Barrie de la Maza
1996 Scholarship from The Government of Navarra, Pamplona Spain

Selected Publications

Peer-Reviewed Original Research Articles
1. Gera S, Dekmezian MS, Duvic M, Tschen J, Vega F, Cho-Vega JH. Blastic plasmacytoid dendritic cell neoplasm;evolving insights in an aggressive hematopoatic malignancy with a prediction of skin involvement. Am J Dermatopathol. In Press.
2. Kunkalla L, Liu Y, Changju Q, Leventaki V, Agarwal NK, Singh R, Vega F. Functional inhibition of BCL2 is needed to increase the susceptibility to apoptosis to SMO Inhibitors in diffuse large B-cell Lymphoma of germinal center subtype. Annals Hematol. In Press. PMID: 23370596.
3. Agarwal NK, Qu C, Kunkalla K, Liy Y, Vega F. Transcriptional Regulation of Serine/Threonine Protein Kinase (AKT) Genes by Glioma-Associated Oncogene Homolog 1. J Biol Chem. In Press. PMID: 23580656.
4. Qu C, Liu Y, Kunkalla K, Singh RR, Blonska M, Lin X, Agarwal NK, Vega F. Trimeric G protein-CARMA1 axis links smoothened, the hedgehog receptor transducer, to NF-KB activation in diffuse large B-cell lymphoma. Blood. In Press.
5. Li S, Feng X, Li T, Zhang S, Zuo Z, Lin P, Konoplev S, Bueso-Ramos CE, Vega F, Medeiros LJ, Yin CC. Extranodal NK/T-cell Lymphoma, Nasal Type: A Report of 73 Cases at MD Anderson Cancer Center. Am J Surg Pathol 37(1):14-23, 1/2013. PMID: 23232851.
6. Ok CH, Singh RR, Vega F. Aberrant activation of the hedgehog signaling pathway in malignant hematological neoplasms. Am J Pathol 180:2-11, 2012. PMID: 22056910.
7. Ramirez E, Singh RR, Kunkalla K, Liu Y, Qu C, Cain C, Multani AS, Lennon PA, Jackacky J, Ho M, Dawud S, Gu J, Yang S, Hu PC, Vega F. Defining causative factors contributing in the activation of hedgehog signaling in diffuse large B-cell lymphoma. Leuk Res 36(10):1267-73, 2012. PMID: 22809693.
8. Greaves WO, Xiao L, Sanchez-Espiridion B, Kunkalla K, Dave KS, Liang CS, Singh RR, Younes A, Medeiros LJ, Vega F. Detection of ABCC1 expression i classical Hodgkin Lymphoma is associated with increased risk of treatment failure using standard chemotherapy protocols. J Hematol Oncol 5:47, 2012. PMID: 22871336.
9. Buglio D, Palakurthi S, Byth K, Vega F, Toader D, Saeh J, Neelapu SS, Younes A. Essential role of TAK1 in regulating mantle cell lymphoma survival. Blood 120:347-55, 2012. PMID: 22649101.
10. Kim Y, Leventaki V, Bhaijee F, Jackson CC, Medeiros LJ, Vega F. Extracavitary/Solid Variant of Primary Effusion Lymphoma. Ann Diagn Pathol 16:441-6, 2012. PMID: 22497739.
11. Kanagal-Shamanna R, Medeiros LJ, Lu G, Wang SA, Manning JT, Lin P, Penn GM, Young KH, You MJ, Vega F, Bassett R, Miranda RN. High-grade B cell lymphoma, unclassifiable, with blastoid features: an unusual morphological subgroup associated frequently with BCL2 and/or MYC gene rearrangements and a poor prognosis. Histopathology 61:945-54, 2012. PMID: 22804688.
12. Sánchez-Espiridión B, Martin-Moreno AM, Montalbán C, Medeiros LJ, Vega F, Younes A, Piris MA, Garcia JF. Immunohistochemical markers for tumor associated macrophages and survival in advanced classical Hodgkin's lymphoma. Haematologica 97:1080-4, 2012. PMID: 22315492.
13. Moretti L, Medeiros LJ, Kunkalla K, Williams MD, Singh RR, Vega F. N-terminal PAX8 polyclonal antibody shows cross-reactivity with N-terminal region of PAX5 and is responsible for reports of PAX8 positivity in malignant lymphomas. Mod Path 25:231-6, 2012.
14. Li C, Thompson MA, Tamaya AT, Zuo Z, Lee J, Vega F, Ford RJ, Pham LV. Over-expression of thioredoxin-1 mediates growth, survival, and chermoresistance aand is a drugable target in diffuse large B-cell lymphoma. Oncotarget 3:314-326, 2012.
15. Meadows SA, Vega F, Kashishian A, Johnson D, Diehl V, Miller LL, Younes A, Lannutti BJ. PI3Kδ inhibitor, GS-1101 (CAL-101), attentuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma. Blood 119:1897-900, 2012.
16. Singh R, Kunkalla K, Qu C, Schlette E, Neelapu S, Samaniego F, Vega F. ABCG2 is a Direct Transcriptional Target of Hedgehog Signaling and Involved in Stroma-Induced Drug Tolerance in Diffuse Large B-Cell Lymphoma. Oncogene 30(49):4874-66, 2011.
17. Drakos E, Singh RR, Rassidakis GZ, Schlette EJ, Li J, Claret FX, Ford RJ, Vega F, Medeiros LJ. Activation of p53 pathway by MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma. Leukemia 25:856-67, 2011.
18. Cho-Vega JH, Tschen JA, Vega F. CD4 CD8 Double-Negative Early Stage Mycosis Fungoides Associated with Primary Cutaneous Follicular Center Lymphoma. J Am Acad Dermatol 65(4):884-6, 2011.
19. Huh YO, Schweighofer CD, Ketterling RP, Knudson RA, Vega F, Kim JE, Luthra R, Keating MJ, Medeiros LJ, Abruzzo LV. Chronic Lymphocytic Leukemia With t(14;19)(q32;q13) Is Characterized by Atypical Morphologic and Immunophenotypic Features and Distinctive Genetic Features. Am J Clin Pathol 135:686-96, 2011. PMID: 21502423.
20. Pham LV, Fu L, Tamayo AT, Bueso-Ramos C, Drakos E, Vega F, Medeiros LJ, Ford RJ. Constitutive BR3 receptor signaling in diffuse large B-cell lymphomas stabilizes NK-{kappa}B-inducing kinase, while activating both canonical and alternative NF-{kappa}B pathways. Blood 117:200-10, 2011.
21. Vishwamitra D, Shi P, Wilson D, Manshouri R, Vega F, Schlette EJ, Amin HM. Expression and effects of inhibition of IGF-IR tyrosine kinase in mantle cell lymphoma. Haematologica 96:871-90, 2011.
22. Drakos E, Leventaki V, Atsaves V, Schlette EJ, Lin P, Vega F, Miranda RN, Claret FX, Medeiros LJ, Rassidakis GZ. Expression of serine 194-phosphorylated Fas-associated death domain protein correlates with proliferation in B-cell non-Hodgkin-type lymphomas. Hum Pathol 42:1117-24, 2011.
23. Hsu C, Vega F, Grimes LM, Hunt KK. Follicular dendritic cell sarcoma and associated myasthemia gravis: true, true, related? J Clin Oncol 29:369-71, 2011.
24. Greaves WO, Kim JE, Singh RR, Drakos E, Kunkalla K, Sánchez-Espiridión B, Garcia JF, Medeiros LJ, Vega F. Glioma associated oncogene homologue 3 (GLI3), a Hedgehog transcription factor, is highly expressed in hodgkin and Reed-Sternberg cells of Classical Hodgkin lymphoma. Hum Pathol 42:1643-52, 2011.
25. Curry LJ, Prieto VG, Jones DM, Vega F, Duvic M, Diwan AH. Transient iatrogenic immunodeficiency-related B-cell lymphoproliferative disorder of the skin in a patient with mycosis fungoides/Sezary syndrome. J Cutan Pathol 38:295-7, 2011.
26. Khokhar FA, Payne WD, Talwalkar SS, Jorgensen J, Bueso-Ramos C, Medeiros LJ, Vega F. Angioimmunoblastic T-Cell Lymphoma in Bone Marrow: A Morphologic and Immunophenotypic Study. Hum Pathol 41:79-87, 2010.
27. Cho-Vega JH, Tschen J, Duvic M, Vega F. Early stage mycosis fungoides variants: Case based review. Ann Diagn Pathol 14:369-85, 2010.
28. Singh RR, Kim JE, Davuluri Y, Drakos-E, Cho-Vega JH, Amin H, Vega F. Hedgehog-signaling pathway contributes to tumor cell survival and proliferation in diffuse large B-cell lymphoma. Leukemia 24:1025-36, 2010.
29. Vega F, Davuluri Y, Cho-Vega JH, Ma S, Wang RU, Multani AS, Drakos I, Pham L, Shen L, Ambrus J, Medeiros LJ, Ford R. Side population contains cells with "tumor-initiating cell" features responsible for lymphoma maintenance and systemic dissemination. J Cell Mol Med 14:1532-45, 2010.
30. Wang SA, Jabbark, Lu G, Chen SS, Galili N, Vega F, Jones D, Raza A, Kantarjian H, Garcia-Manero G, McDonnell TJ, Medeiros LJ. Trisomy 11 in myelodysplastic syndromes defines a unique group of disease with aggressive clinicopathologic features. Leukemia 24:740-7, 2010.
31. Vega F, Medeiros LJ. V(D)J recombination and staggered DNA breaks: guilty again. Blood 115:2121-2, 2010.
32. Kim JE, Singh RR, Cho-Vega JH, Drakos E, Davuluri Y, Fayad L, Medeiros LJ, Vega F. Hedgehog (SHH)-signaling proteins and ATP binding cassette (ABC) are aberrantly expressed in diffuse large B-cell lymphoma. Mod Pathol 10:1312-20, 2009.
33. Falchook G, Vega F, Dang N, Samaniego F, Rofriguez M, Champlin R, Hosing C, Verstovsek S, Pro B. Hepatosplenic gamma-delta T-cell lymphoma: clinicopathological features and treatment. Ann Oncol 20:1080-1085, 2009.
34. Drakos E, Rassidakis RZ, Leventaki V, Cotta C, Vega F, Medeiros LJ. Nodular Lymphocyte predominant Hodgkin lymphoma with clusters of L&H-like cells, acute inflammation, and fibrosis: a syncitial variant. Am J Surg Pathol 33:1725-31, 2009.
35. Singh RR, Cho-Vega JH, Davuluri y, Ma S, Kasbidi F, Milito C, Lennon PA, Drakos E, Medeiros LJ, Luthra R, Vega F. Sonic Hedgehog signaling pathway is activated in ALK-positive anaplastic large cell lymphoma. Cancer Res 69:2550-8, 2009.
36. Quintas-Cardama A, Tong W, Manshouri T, Vega F, Lennon PA, Cools J, Gilliland DG, Lee F, Cortes J, Kantarjian H, Garcia-Manero G. Activity of tyrosine kinase inhibitors against human nup214-abl-positive T-cell malignancies. Leukemia 22:1117-1124, 2008.
37. Cho-Vega JH, Vega F, Medeiros LJ. An Attractive Therapeutic Target, mTOR Pathway, for an Effective Combinatorial Cancer Therapy in Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma. Adv Anat Pathol 15:105-12, 2008.
38. Cho-Vega JH, Medeiros LJ, Prieto VG, Vega F. Leukemia Cutis. Am J Clin Pathol 129:130-42, 2008.
39. Huh Yang, I-Chun Lin K, Vega F, Schlette E, Yin C, Keating M, Luthra R. Medeiros LJ and Abruzzo L. MYC translocation in chronic lymphocytic leukemia is associated with increased prolymphocytes and a poor prognosis. Br J Haematol 142:36-44, 2008.
40. Vega F, Cho-Vega JH, Lennon PA, Luthra MG, Bailey J, Breeden M, Jones D, Medeiros LJ, Luthra R. Splenic Marginal Zone Lymphomas are characterized by loss of Interstitial Regions of Chromosome 7q,7q31.32 and 7q36.2, that include protection of Telomere 1 (POT1) and Sonic Hedgehog (SHH) Genes. Br J Haematol 142:216-226, 2008.
41. Jain N, Hubbard J, Vega F, Vidal G, Garcia-Manero G, Borthakur G. Spontaneous Remission of Acute Myeloid Leukemia:Report of Three Cases and Review of the Literature. Clin Leuk 2:64-67, 2008.
42. Vega F, Medeiros LJ, Davuluri R, Alkan S, Abruzzo LV. t(8;13)-positive bilineal lymphomas:report of six cases. Am J Surg Pathol 32:14-20, 2008.
43. Cho-Vega JH, Vega F, Schwartz MR, Prieto VG. Expression of dicarbonyl/L-xylulose reductase (DCXR) in human skin and melanocytic lesions:morphological studies supporting cell adhesion function of DCXR. J Cutan Pathol 34:535-542, 2007.
44. Vega F, Medeiros LJ, Gaulard P. Hepatosplenic and other gamma delta T-cell Lymphomas. Am J Clin Pathol 127:869-80, 2007.
45. Lin P, Jones D, Medeiros LJ, Chen W, Vega F, Luthra R. Activating FLT3 Mutations are detectable in Chronic and Blast Phase of Chronic Myeloproliferative Disorders other than Chronic Myeloid Leukemia. Am J Clin Pathol 126:1-4, 2006. PMID: 16938665.
46. Vega F, Medeiros LJ, Leventaki V, Atwell C, Cho-Vega JH, Tian L, Claret FX, Rassidakis GZ. Activation of mTOR Signaling Pathway Contributes to Tumor Cell Survival in ALK-Positive Anaplastic Large Cell Lymphoma. Cancer Res 66:6589-97, 2006.
47. Vega F, Chang CC, Schwartz MR, Verm R, Preti HA, Etwon A, Younes M, Jaffe ES. Atypical NK-cell proliferation of the gastrointestinal tract in a patient with antigliadin antibodies but not celiac disease. Am J Surg Pathol 4:539-544, 2006.
48. Cho-Vega JH, Vega F, Rassidakis G, Medeiros LJ. Primary Cutaneous Marginal Zone B-Cell Lymphoma. Am J Clin Pathol 125:S38-S49, 2006.
49. Vega F, Padula A, Valbuena JR, Stancu M, Jones D, Medeiros LJ. Systemic lymphomas involving the pleura. A Clinicopathologic study of 34 cases diagnosed by pleural biopsy. Arch Pathol Lab Med 130:1497-1502, 2006.
50. Vega F, Coombes KR, Thomazy VA, Patel K, Lang W, Jones D. Tissue-Specific Function of Lymph Node Fibroblastic Reticulum Cells. Pathobiology 73:71-81, 2006.
51. Vega F, Lin P, Medeiros LJ. Extranodal lymphomas of the head and neck. Ann of Diagn Pathol 9:340-350, 2005.
52. Vega F, Chang CC, Medeiros LJ, Udden MM, Cho-Vega JH, Lau CC, Finch C, Vilchez RA, McGregor DK, Jorgensen JL. Plasmablastic lymphomas and plasmablastic plasma cells myelomas have nearly identical immunophenotypic profiles. Mod Pathol 18:806-815, 2005.
53. Cho-Vega JH, Rassidakis GZ, Amin HM, Tsioli P, Spurgers K, Remache YK, Vega F, Goy AH, Gilles F, Medeiros LJ. Suppressor of cytokine signaling 3 expression in anaplastic cell lymphoma. Leukemia 18:1872-1878, 2004.
54. Vega F, Medeiros LJ. Chromosomal translocations involved in non-Hodgkin lymphomas. Arch Pathol Lab Med 127:1148-1160, 2003.
55. Thomazy VA, Vega F, Medeiros LJ, Davis PJ, Jones D. Phenotypic modulation of the stromal reticular network in normal and neoplastic lymph nodes:transglutaminase reveals coordinate regulation. Am J Pathol 163:165-174, 2003.
56. Jones D, Vega F, Sarris AH, Medeiros LJ. A CD4 and CD8 "double-negative" immunophenotype in cutaneous T-cell lymphoma is predictive of an aggressive clinical course. Am J Surg Pathol 26:225-231, 2002.
57. Vega F, Luthra R, Medeiros LJ, Dunmire V, Lee SJ, Duvic M, Jones D. Clonal heterogeneity in mycosis fungoides and its relationship to clinical course. Blood 100:3369-3373, 2002.
58. Abruzzo LV, Rosales CM, Medeiros LJ, Vega F, Luthra R, Manning JT, Keating MJ, Jones D. Epstein-Barr virus positive B-cell lymphoproliferative disorders arising in immunodeficient patients previously treated with fludarabine for low-grade B-cell neoplasms. Am J Surg Pathol 26:630-636, 2002.
59. Sen F, Vega F, Medeiros LJ. Molecular genetic methods in the diagnosis of hematologic neoplasms. Semin Diagn Pathol 19:72-93, 2002.
60. Stancu M, Jones D, Vega F, Medeiros LJ. Peripheral T-cell lymphoma arising in the liver. Am J Clin Pathol 118:574-581, 2002.
61. Onciu M, Lai R, Vega F, Bueso-Ramos C, Medeiros LJ. Precursor T-cell acute lymphoblastic leukemia in adults. Am J Clin Pathol 117:252-258, 2002.
62. Sanchez-Vega B, Vega F, Medeiros LJ, Lee MS, Luthra R. Quantification of BCL-2/JH fusion sequences and a control gene by multiplex real-time PCR coupled with automated amplicon sizing by capillary electrophoresis. J Mol Diagn 4:223-229, 2002.
63. Sanchez-Vega B, Vega F, Hai S, Medeiros LJ, Luthra R. Real-time t(14;18) PCR assay combined with high resolution PCR fragment analysis: A novel approach to monitor disease/tumor burden in follicular lymphoma patients. Mod Pathol 15:441-453, 2002.
64. Vega F, Orduz R, Medeiros LJ. Roles of common chromosomal translocations in non-Hodgkin's lymphomas. Pathology 34:397-409, 2002.
65. Vega F, Medeiros LJ, Luthra R. Taqman PCR in the detection and of chromosomal translocations in follicular lymphoma, mantle cell lymphoma and chronic myeloid leukemia. Internet J Pathol 2(1), 2002.
66. Vega F, Medeiros LJ, Lang WH, Mansoor A, Bueso-Ramos C, Jones D. The stromal composition of malignant lymphoid aggregates in bone marrow: variations in architecture and phenotype in different in different B-cell tumors. Br J Haematol 117:569-576, 2002.
67. Vega F, Medeiros LJ, Jones D, Abruzzo LV, Lai R, Manning J, Dunmire V, Luthra R. A novel 4-color PCR assay to assess T-cell receptor gamma gene rearrangements in lymphoproliferative lesions. Am J Clin Pathol 116:17-24, 2001.
68. Vega F, Medeiros LJ. Chromosomal translocations in Non-Hodgkin's lymphomas (Part I). Patologia 34:277-286, 2001.
69. Vega F, Medeiros LJ. Chromosomal translocations in Non-Hodgkins's lymphomas (Part II). Patologia 34:353-366, 2001.
70. Vega F, Medeiros LJ, Bueso-Ramos C, Jones D, Lai R, Luthra R, Abruzzo LV. Hepatosplenic T-cell lymphoma in bone marrow: An intra-sinusoidal neoplasm with blastic cytologic features. Am J Clin Pathol 116:410-419, 2001.
71. Vega F, Medeiros LJ. Marginal zone B-cell lymphoma of extranodal MALT-type. Molecular genetics provides new insides into pathogenesis. Adv Anat Pathol 8:313-326, 2001.
72. Vega F, Medeiros LJ, Abruzzo LV. Primary paratesticular lymphoma:a report of two cases and literature review. Arch Patol Lab Med 125:428-432, 2001.
73. Calvo M, Firvida JL, Vega F, Salgado M, Garcia Mata J, Ruben M, Barreiro A. Wilms tumor in the adult. Arch Esp Urol 54:370-374, 2001.
74. Vega F, Diaz MS. Extramedullary hematopoiesis in polyposis. Gastrointest Endosc 51:330-331, 2000.
75. Olivieri DN, Vega F. Image prototype similarity matching for lymph node hematopathology. Proceedings - International Conference on Pattern Recognition 15(2):279-282, 2000.
76. Rodriguez-Gomez M, Fernandez-Sueiro JL, Willisch A, Fernandez-Dominguez L, Lopez-Barros G, Vega F. Multifocal dactylitis as the sole clinical expression of sarcoidosis. J Rheumatol 27:245-247, 2000. PMID: 10648047.
77. Panizo A, Sola I, Vega F, de Alava E, Lozano MD, Idoate MA, Pardo-Mindan FJ. Predicting metastatic risk of gastrointestinal stromal tumors:role of cell proliferation and cell cycle regulatory proteins. Int J Surg Pathol 8:133-144, 2000.
78. Vega F, Lozano MD, Alcade J, Pardo-Mindan FJ. Role of the inmunohistochemical and molecular biology in necrotic lymph node. Virchows Arch 434:245-248, 1999.
79. Vega F, Panizo A, Diez, Pardo-Mindan FJ. Susceptibility to apoptosis of arterioles and capillaries in adult spontaneously hypertensive rats. Am J Hypertens 12:815-820, 1999.
80. Pastrana J, Conchillo MA, Vega F, Beloqui O. Granulomatosis linfomatoide pulmonar asociada a SIDA. Descripcion de un caso y revision de la literatura. An Med Interna 15:487-489, 1998.
81. Diez J, Panizo A, Hernandez M, Vega F, Sola I, Fortuno MA, Pardo J. Cardiomyocyte apoptosis and cardiac angiotensin-converting enzyme in spontaneously hypertensive rats. Hypertension 30:1029-1034, 1997.
82. Idoate MA, Vega F. Diagnostico de las enfermedades neurometabolicas y neurodegenerativas mediante biopsia cutanea. Rev Neurol 25:S269-S280, 1997.
83. Perez-Requena J, Vega F, Guezmez Domingo A, Ruiz ML, Paloma Gonzalez MJ, Diaz l. Gliomatosis peritoneal: presentacion de los casos asociados a gliomatosis ganglionar y ovarica y elevacion de las concentraciones de alfa-fetoproteina. Patologia 30:150-153, 1997.
84. Panizo A, Vega F. Glosario de biologia molecular. Patologia 30:259-260, 1997.
85. Arriagada C, Leyes, M, Valenti JR, Vega F. Papel de la artroscopia en la condrocalcinosis. Cuadren Artroscopia 4:21-25, 1997.
86. Vega F, Errasti F, Pardo-Mindan FJ. Renal Transplantation from a donor with a Nail-Patella Syndrome. Nephr Dyal Transp 12:1742-1744, 1997.
87. Panizo A, Vega F. Revision de la tecnica del TUNEL. Patologia 30:243-245, 1997.
88. Vega F, Diaz L, Castro l, Panizo A, Sierrasesumaga L, Pardo-Mindan FJ. Metastasis ganglionares de osteosarcomas. Rev Med Univ Navarra 40:27-30, 1996.
89. Vega F, Sierrasesumaga L, Panizo A, Diaz L, Foncillas J. Metastasis Pulmonares de Osteosarcoma:Factores pronosticos. Patologia 29:325-331, 1996.
90. Arias M, Abreu JA, Iglesias A, Longo J, Lecumberri F, Vega F. Primary amyloidosis presenting as renal infarction. Eur-Radiol 6:346-8, 1996.
91. Vega F. Pseudomixoma Peritonei. Rev Med Univ Navarra 2:64, 1996.
92. Garcia-Rayo S, Gurpide A, Vega F, Brugarolas A. Regresion tumoral espontanea en un paciente con mieloma multiple. Comunicacion de un caso adicional. Rev Med Univ Navarra 40:27-30, 1996.

Letters to the Editor
1. Lamela J, Vega F. Immunologic aspects of chronic obstuctive pulmonary disease. N Eng J Med 361:1024, 2009.
2. Lamela J, Vega F, Blanco J. Airway obstruction in chronic obstructive pulmonary disease. N Eng J Med 351:1459-1461, 2004.
3. Vega F. Uterine Rupture. N Eng J Med 339:268-269, 1998.

Grant & Contract Support

Title: Cross-talking between Smoothened and NF-KB Signaling Pathway in Diffuse large B Cell Lymphoma
Funding Source: UT MD Anderson Institutional Research Fund Application
Role: Principal Investigator
Duration: 7/2012 - 6/2013
 
Title: Hedgehog Signaling a Therapeutic Target for Diffuse Large B-cell Lymphoma, Translational Research Program, Effort 1% (0.12 calendar months)
Funding Source: Leukemia and Lymphoma Society
Role: Principal Investigator
Duration: 10/1/2010 - 9/30/2013
 
Title: K08 award. Role of Sonic Hedgehog Signaling in Diffuse Large B-Cell Lymphomas. Effort 75% (9 calendar months)
Funding Source: NIH/NCI
Role: 1K08CA14315101 Physician-Scientist
Duration: 9/8/2010 - 8/31/2013
 
Title: Hedgehog Signaling a Therapeutic Target for Diffuse Large B-Cell Lymphoma, Effort 1% (0.12 calendar)
Funding Source: Developmental Research Award SPORE Lymphoma
Role: Principal Investigator
Duration: 5/2010 - 5/2011
 
Title: Targeting Sonic Hedgehog Signaling to Overcome Chemoresistance in Diffuse Large B-Cell Lymphoma, Effort 1% (0.12 calendar months)
Funding Source: Lauri Strauss Leukemia Foundation, New York
Role: Co-Principal Investigator and mentor of Dr. Rajesh Singh (Instructor, Department of Hematopathology)
Duration: 4/1/2010 - 3/31/2011
 
Title: Sonic Hedgehog Signaling Pathway as a Therapeutic Target in Diffuse Large B-cell Lymphoma, Effort 10% (1.2 calendar months)
Funding Source: UT MD Anderson Cancer Center Institutional Research Fund Application
Role: Principal Investigator
Duration: 7/2008 - 7/2010
 
Title: Identification and Characterization of Tumor Initiating Cells in Chronic Lymphocytic Leukemia, Effort 10% (1.2 calendar months)
Funding Source: CLL Global Research Foundation
Role: Principal Investigator
Duration: 12/19/2007 - 12/28/2009

Last updated: 3/20/2013